Untreatable asthma, also known as severe asthma or uncontrollable asthma, refers to the difficulty of achieving control targets, or the need for high doses of medications to maintain control, or frequent acute seizures, or frequent emergency and hospitalized asthma. Although untreatable asthma accounts for less than 5%-10% of asthma patients, the burden of disease, frequent acute outbreaks, poor quality of life, high risk of death, are the difficulty and focus of managing asthma. Some patients are not really 'difficult to treat', but there are factors that affect their effectiveness: the treatment depends on sexual dysfunction (drugs not given in a timely manner), incorrect techniques of inhalation, persistent exposure to allergens or stimuli (dust, bacteria, tobacco smoke, occupational allergens), uncontrolled syndromes (allergic nasal inflammation, nosebleeds, gastrointestinal tract reflux disease, obesity, sleep apnea, anxiety), unreasonable use of medication, and so on.
Clinical manifestations of uncontrollable asthma are similar to, but more severe than, normal asthma: recurrent episodes of asthma, shortness of breath, coughing, coughing, heavy at night and early morning; frequent seizures, requiring long-term high doses of medications and even frequent oral hormones; acute seizures, severe breathing difficulties, lifelong breathing difficulties, sweating, consciousness disorders, asthma severity; decreased patient endurance, increased absence from school, pulmonary function (FEV1) and marked impairment of quality of life. Diagnosis of uncontrollable asthma requires a systematic assessment of the 'uncontrollable' causes of asthma under the premise of confirming the asthma diagnosis. Assessments include: pulmonary function, respiratory relaxation tests, stimulation tests, breathing oxygen, blood-solid cell counts, allergen testing, chest CT, pump-induced analysis, and other clear inflammatory patterns; assessing dependence on sex, inhalation techniques, environmental exposure and synapses; screening for acidic pulmonary multiple sclerosis, varicose vein pneumonia, and other diseases that may simulate asthma.
Systematic evaluation, excluding corrective factors, makes it difficult for controllers to diagnose severe asthma. Treatment of uncontrollable asthma emphasizes 'evaluation-treatment-re-evaluation' of cyclical and individualized treatment. First, correction of reversible factors: strengthening patient education, standardizing techniques for absorption, improving addiction, avoiding allergens, combined therapy.
Anti-IL-5/IL-5R monotherapy (Mephalipid monotherapy; Benalyl monotherapy) is used for acidopathic granulocytes; anti-IL-4R monotherapy (Degree of Prejuvenation) is significantly effective against type 2 inflammatory asthma, reducing acute seizures and hormone dependency. Interventive treatments such as thromboembolism are available for some untreatable patients. Acute seizures require direct and timely treatment for acute seizures.
Management of acute asthma requires physician guidance, patient active co-operation and long-term follow-up. Adherence to prescribed medications, no self-interruption or reduction; regular review of lung function and inflammatory indicators, and timely adjustment of regimens. Through prescribed evaluations and individualized treatment, especially the use of bio-focused therapies, many patients with incurable asthma can achieve good control, significantly improve quality of life, and reduce acute seizures.
[!--page.url--]